Cell-based assay design for high-content screening of drug candidates

Journal of Microbiology and Biotechnology

Volumn 26, Issue 2, 2015, Pages 213-225

  Nierode, Gregory ^a   Kwon, Paul S ^a   Dordick, Jonathan S ^a   Kwon, Seok Joon ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

3D cell culture system; Cell based assay; Drug discovery; High content screening (HCS)

Indexed keywords

CELL ASSAY; CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; FLUORESCENCE ANALYSIS; HIGH CONTENT SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REPORTER GENE; REVIEW; RNA INTERFERENCE; BIOASSAY; CELL CULTURE TECHNIQUE; DRUG DEVELOPMENT; PRECLINICAL STUDY; PROCEDURES; SOFTWARE;

BIOLOGICAL ASSAY; CELL CULTURE TECHNIQUES; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; IMMUNOHISTOCHEMISTRY; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE; SOFTWARE;

EID: 84975691086     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1508.08007     Document Type: Review

References (120)

1. Arkin MR, Glicksman MA, Fu H, Havel JJ, Du Y. 2004. Inhibition of protein-protein interactions: non-cellular assay formats. In Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, et al. (eds.). Assay Guidance Manual. Bethesda, MD.
2. Arkin MR, Wells JA. 2004. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3: 301-317.
3. Arnone MI, Dmochowski IJ, Gache C. 2004. Using reporter genes to study cis-regulatory elements. Methods Cell Biol. 74: 621-652.
4. Aronson JK. 2007. Old drugs - new uses. Br. J. Clin. Pharmacol. 64: 563-565.
5. Ashburn TT, Thor KB. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug. Discov. 3: 673-683.
6. Aswendt M, Adamczak J, Tennstaedt A. 2014. A review of novel optical imaging strategies of the stroke pathology and stem cell therapy in stroke. Front. Cell. Neurosci. 8: 226.
7. Barrangou R, Birmingham A, Wiemann S, Beijersbergen RL, Hornung V, Smith A. 2015. Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Res. 43: 3407-3419.
8. Boland MV, Murphy RF. 2001. A neural network classifier capable of recognizing the patterns of all major subcellular structures in fluorescence microscope images of HeLa cells. Bioinformatics 17: 1213-1223.
9. Boutros M, Ahringer J. 2008. The art and design of genet ic screens: RNA interference. Nat. Rev. Genet. 9: 554-566.
10. Bronstein I, Fortin J, Stanley PE, Stewart GS, Kricka LJ. 1994. Chemiluminescent and bioluminescent reporter gene assays. Anal. Biochem. 219: 169-181.
11. Campeau E, Gobeil S. 2011. RNA interference in mammals: Behind the screen. Brief. Funct. Genomics 10: 215-226.
12. Canton I, Cole DM, Kemp EH, Watson PF, Chunthapong J, Ryan AJ, et al. 2010. D evelopment of a 3D human in vitro skin co-culture model for detecting irritants in real-time. Biotechnol. Bioeng. 106: 794-803.
13. Celli JP, Rizvi I, Blanden AR, Massodi I, Glidden MD, Pogue BW, Hasan T. 2014. An imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour models. Sci. Rep. 4: 3751.
14. Chen L, Feany MB. 2005. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8: 657-663.
15. Chong CR, Sullivan DJ Jr. 2007. New uses for old drugs. Nature 448: 645-646.
16. Clemons PA. 2004. Complex phenotypic assays in highthroughput screening. Curr. Opin. Chem. Biol. 8: 334-338.
17. Cong L, Ran FA, Cox D, Lin S, Barret to R, Habib N, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823.
18. Conrad C, Erfle H, Warnat P, Daigle N, Lorch T, Ellenberg J, et al. 2004. Automatic identification of subcellular phenotypes on human cell arrays. Genome Res. 14: 1130-1136.
19. Conrad C, Gerlich DW. 2010. Automated microscopy for high-content RNAi screening. J. Cell Biol. 188: 453-461.
20. Crisman TJ, Parker CN, Jenkins JL, Scheiber J, Thoma M, Kang ZB, et al. 2007. Underst anding false p osit ives i n reporter gene assays: In silico chemogenomics approaches to prioritize cell-based HTS data. J. Chem. Inf. Model. 47: 1319-1327.
21. Dhaliwal A, Oshita V, Segura T. 2013. Transfection in the third dimension. Integr. Biol. (Camb.) 5: 1206-1216.
22. Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, et al. 2007. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat. Chem. Biol. 3: 268-273.
23. Duryagina R, Anastassiadis K, Maitz MF, Gramm S, Schneider S, Wobus M, et al. 2014. Cellular reporter systems for high-throughput screening of interactions between bioactive matrices and human mesenchymal stromal cells. Tissue Eng. Part C Methods 20: 828-837.
24. Echeverri CJ, Perrimon N. 2006. High-throughput RNAi screening in cultured cells: A user’s guide. Nat. Rev. Genet. 7: 373-384.
25. Edwards BS, Sklar LA. 2015. Flow cytometry: Impact on early drug discovery. J. Biomol. Screen. 20: 689-707.
26. Elliot tD A, B raam S R, K out iss K, N g ES, Jenny R, Lagerqvist EL, et al. 2011. NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat. Methods 8: 1037-1040.
27. Enikolopov G, Overstreet-Wadiche L, Ge S. 2015. Viral and transgenic reporters and genetic analysis of adult neurogenesis. Cold Spring Harb. Perspect. Biol. 7: a018804.
28. Erfle H, Neumann B, Liebel U, Rogers P, Held M, Walter T, et al. 2007. Reverse transfection on cell arrays for high content screening microscopy. Nat. Protoc. 2: 392-399.
29. Erfle H, Neumann B, Rogers P, Bulkescher J, Ellenberg J, Pepperkok R. 2008. Work flow for multiplexing siRNA assays by solid-phase reverse transfection in multiwell plates. J. Biomol. Screen. 13: 575-580.
30. Erfle H, Simpson JC, Bastiaens PI, Pepperkok R. 2004. siRNA cell arrays for high-content screening microscopy. Biotechniques 37: 454-458, 460, 462.
31. Falcon BL, Stewart J, Ezell S, Hanson J, Wijsman J, Ye X, et al. 2013. High-content multiplexed tissue imaging and quantification for cancer drug discovery. Drug Discov. Today 18: 510-522.
32. Feng Y, Mitchison TJ, Bender A, Young DW, Tallarico JA. 2009. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat. Rev. Drug Discov. 8: 567-578.
33. Fernandes TG, Diogo MM, Clark DS, Dordick JS, Cabral JM. 2009. High-throughput cellular microarray platforms: Applications in drug discovery, toxicology and stem cell research. Trends Biotechnol. 27: 342-349.
34. Fernandes TG, Kwon SJ, Lee MY, Clark DS, Cabral JM, Dordick JS. 2008. On-chip, cell-based microarray immunofluorescence assay for high-throughput analysis of target proteins. Anal. Chem. 80: 6633-6639.
35. Fields S, Song O. 1989. A novel genetic system to detect protein-protein interactions. Nature 340: 245-246.
36. Fishman MC, P ort er JA. 2 005. P harmaceuticals: a n ew grammar for drug discovery. Nature 437: 491-493.
37. Galarneau A, Primeau M, Trudeau LE, Michnick SW. 2002. Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein-protein interactions. Nat. Biotechnol. 20: 619-622.
38. Ganesan AK, Ho H, Bodemann B, Petersen S, Aruri J, Koshy S, et al. 2008. Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. PLoS Genet. 4: e1000298.
39. Gasparri F, G alvani A. 2010. I mage-based h igh-cont ent reporter assays: limitations and advantages. Drug Discov. Today Technol. 7: e1-e94.
40. Genovesio A, Kwon YJ, Windisch MP, Kim NY, Choi SY, Kim HC, et al. 2011. Automated genome-widevisualprofiling of cellular proteins involved in HIV infection. J. Biomol. Screen. 16: 945-958.
41. Ghosh I, Hamilton AD, Regan L. 2000. Antiparallel leucine zipper-directed protein reassembly: Application to the green fluorescent protein. J. Am. Chem. Soc. 122: 5658-5659.
42. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, et al. 2008. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA 105: 763-768.
43. Hamdi A, Colas P. 2012. Yeast two-hybrid methods and their applications in drug discovery. Trends Pharmacol. Sci. 33: 109-118.
44. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. 2014. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32: 40-51.
45. Haycock JW. 2011. 3D cell culture: a review of current approaches and techniques. Methods Mol. Biol. 695: 1-15.
46. Hendriks G, Atallah M, Morolli B, Calleja F, Ras-Verloop N, Huijskens I, et al. 2012. The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. Toxicol. Sci. 125: 285-298.
47. Hendriks G, van de Water B, Schoonen W, Vrieling H. 2013. Cellular-signaling pathways unveil the carcinogenic potential of chemicals. J. Appl. Toxicol. 33: 399-409.
48. Herce HD, Deng W, Helma J, Leonhardt H, Cardoso MC. 2013. Visualization and targeted disruption of protein interactions in living cells. Nat. Commun. 4: 2660.
49. Hibbitts A, Lieggi N, McCabe O, Thomas W, Barlow J, O’Brien F, Cryan SA. 2011. Screening of siRNA nanoparticles for delivery to airway epithelial cells using high-content analysis. Ther. Deliv. 2: 987-999.
50. Hofman F. 2002. Immunohistochemistry. Curr. Protoc. Immunol. Chapter 21: Unit 21.4.
51. Horvath P, Barrangou R. 2010. CRISPR/Cas, the immune system of bacteria and archaea. Science 327: 167-170.
52. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. 2013. DNA targeting specificity of RNAguided Cas9 nucleases. Nat. Biotechnol. 31: 827-832.
53. Hughes JP, Rees S, Kalindjian SB, Philpott KL. 2011. Principles of early drug discovery. Br. J. Pharmacol. 162: 1239-1249.
54. Hynds RE, Giangreco A. 2013. Concise review: the relevance of human stem cell-derived organoid models for epithelial translational medicine. Stem Cells 31: 417-422.
55. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, Auld DS. 2007. High-throughput screening assays for t he ident ification o f chemical p robes. Nat. Chem. Biol. 3: 466-479.
56. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS. 2006. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 12: 1179-1187.
57. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816-821.
58. Johnsson N, Varshavsky A. 1994. Split ubiquitin as a sensor of protein interactions in vivo. Proc. Natl. Acad. Sci. USA 91: 10340-10344.
59. Karlsson HL, Gliga AR, Calleja FM, Goncalves CS, Wallinder IO, Vrieling H, et al. 2014. Mechanism-based genotoxicity screening of metal oxide nanoparticles using the ToxTracker panel of reporter cell lines. Part. Fibre Toxicol. 11: 41.
60. Korn K, Krausz E. 2007. Cell-based high-content screening of small-molecule libraries. Curr. Opin. Chem. Biol. 11: 503-510.
61. Krausz E. 2007. High-content siRNA screening. Mol. Biosyst. 3: 232-240.
62. Krausz E, Korn K. 2008. High-cont ent siRNA screening for target identification and validation. Expert Opin. Drug Discov. 3: 551-564.
63. Kumar R, Conklin DS, Mittal V. 2003. High-throughput selection of effective RNAi probes for gene silencing. Genome Res. 13: 2333-2340.
64. Kwon SJ, Lee DW, Shah DA, Ku B, Jeon SY, Solanki K, et al. 2014. High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening. Nat. Commun. 5: 3739.
65. Ledford H. 2011. Translational research: 4 ways to fix the clinical trial. Nature 477: 526-528.
66. Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C, et al. 1998. Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 273: 34970-34975.
67. Loo LH, Wu LF, Altschuler SJ. 2007. Image-based multivariate profiling of drug responses from single cells. Nat. Methods 4: 445-453.
68. Machleidt T, Whitney P, Bi K. 2009. Multiplexing of pathway-specific beta-lactamase reporter gene assays by optical coding with Qtracker nanocrystals. J. Biomol. Screen. 14: 845-852.
69. Mali P, Esvelt KM, Church GM. 2013. Cas9 as a versatile tool for engineering biology. Nat. Methods 10: 957-963.
70. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. 2013. RNA-guided human genome engineering via Cas 9. Science 339: 823-826.
71. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, et al. 2006. TRANSFAC and i t s module TRANSCompel: Transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34: D108-D110.
72. Meacham CE, Morrison SJ. 2013. Tumour heterogeneity and cancer cell plasticity. Nature 501: 328-337.
73. Meli L, Barbosa HS, Hickey AM, Gasimli L, Nierode G, Diogo MM, et al. 2014. Three-dimensional cellular microarray platform for human neural stem cell differentiation and toxicology. Stem Cell Res. 13: 36-47.
74. Michnick SW, Ear PH, Landry C, Malleshaiah MK, Messier V. 2010. A toolkit of protein-fragment complementation assays for studying and dissecting large-scale and dynamic protein-protein interactions in living cells. Methods Enzymol. 470: 335-368.
75. Michnick SW, Ear PH, Manderson EN, Remy I, Stefan E. 2007. Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat. Rev. Drug Discov. 6: 569-582.
76. Michnick SW, Remy I, Campbell-Valois FX, Vallee-Belisle A, Pelletier JN. 2000. Detection of protein-protein interactions by protein fragment complementation strategies. Methods Enzymol. 328: 208-230.
77. Mohr SE, Perrimon N. 2012. RNAi screening: new approaches, understandings, and organisms. Wiley Interdiscip. Rev. RNA 3: 145-158.
78. Mohr SE, Smith JA, Shamu CE, Neumuller RA, Perrimon N. 2014. RNAi screening comes of age: improved techniques and complementary approaches. Nat. Rev. Mol. Cell Biol. 15: 591-600.
79. Narayanan K, Chen Q. 2011. Bacterial artificial chromosome mutagenesis using recombineering. J. Biomed. Biotechnol. 2011: 971296.
80. Naylor LH. 1999. Reporter gene technology: The future looks bright. Biochem. Pharmacol. 58: 749-757.
81. Neumann B, Held M, Liebel U, Erfle H, Rogers P, Pepperkok R, Ellenberg J. 2006. High-throughput RNAi screening by time-lapse imaging of live human cells. Nat. Methods 3: 385-390.
82. Ohtsuka M, Kimura M, Tanaka M, Inoko H. 2009. Recombinant DNA technologies for construction of precisely designed transgene constructs. Curr. Pharm. Biotechnol. 10: 244-251.
83. Pampaloni F, Reynaud EG, Stelzer EH. 2007. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 8: 839-845.
84. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg S R, S chacht AL. 2010. H ow t o improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9: 203-214.
85. Pawson T, Nash P. 2000. Protein-protein interactions define specificity in signal transduction. Genes Dev. 14: 1027-1047.
86. Pelkmans L, Fava E, Grabner H, Hannus M, Habermann B, Krausz E, Zerial M. 2005. Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature 436: 78-86.
87. Pelletier JN, Campbell-Valois FX, Michnick SW. 1998. Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments. Proc. Natl. Acad. Sci. USA 95: 12141-12146.
88. Perfetto SP, Chattopadhyay PK, Roederer M. 2004. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4: 648-655.
89. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ. 2004. Multidimensional drug profiling by automated microscopy. Science 306: 1194-1198.
90. Rao VS, Srinivas K, Sujini GN, Kumar GN. 2014. Proteinprotein interaction detection: methods and analysis. Int. J. Proteomics 2014: 147648.
91. Remy I, Michnick SW. 2006. A highly sensitive proteinprotein interaction assay based on Gaussia luciferase. Nat. Methods 3: 977-979.
92. Remy I, Wilson IA, Michnick SW. 1999. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283: 990-993.
93. Ren Q, Li C, Yuan P, Cai C, Zhang L, Luo GG, Wei W. 2015. A dual-reporter system for real-time monitoring and high-throughput CRISPR/Cas9 library screening of the hepatitis C virus. Sci. Rep. 5: 8865.
94. Ryan DP, Matthews JM. 2005. Protein-protein interactions in human disease. Curr. Opin. Struct. Biol. 15: 441-446.
95. Samsel L, Dagur PK, Raghavachari N, Seamon C, Kato GJ, McCoy JP Jr. 2013. Imaging flow cytomet ry for morphologic and phenotypic characterization of rare circulating endothelial cells. Cytometry B Clin. Cytom. 84: 379-389.
96. Sato M, Kawai Y, Umezawa Y. 2007. Genetically encoded fluorescent indicators to visualize protein phosphorylation by extracellular signal-regulated kinase in single living cells. Anal. Chem. 79: 2570-2575.
97. Sato M, Ozawa T, Inukai K, Asano T, Umezawa Y. 2002. Fluorescent indicators for imaging protein phosphorylation in single living cells. Nat. Biotechnol. 20: 287-294.
98. Shalem O, S anjana N E, H artenian E, S hi X, Scot t DA, Mikkelsen TS, et al. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343: 84-87.
99. Shalem O, Sanjana NE, Zhang F. 2015. High-throughput functional genomics using CRISPR-Cas 9. Nat. Rev. Genet. 16: 299-311.
100. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. 2004. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma s p. red f luorescent protein. Nat. Biotechnol. 22: 1567-1572.
101. Silva JM, Mizuno H, Brady A, Lucito R, Hannon GJ. 2004. RNA interference microarrays: high-throughput loss-offunction genetics in mammalian cells. Proc. Natl. Acad. Sci. USA 101: 6548-6552.
102. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. 2006. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3: 995-1000.
103. Sonnichsen B, Koski LB, Walsh A, Marschall P, Neumann B, Brehm M, et al. 2005. Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Nature 434: 462-469.
104. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99: 5515-5520.
105. Swinney DC, Anthony J. 2011. How were new medicines discovered?Nat. Rev. Drug Discov. 10: 507-519.
106. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, et al. 2005. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 3: e128.
107. Ting AY, Kain KH, Klemke RL, Tsien RY. 2001. Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells. Proc. Natl. Acad. Sci. USA 98: 15003-15008.
108. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S. 2011. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 136: 473-478.
109. Wade M. 2015. High-throughput silencing using the CRISPR-Cas9 system: a review of the benefits and challenges. J. Biomol. Screen. 20: 1027-1039.
110. Walsh DP, Chang YT. 2006. Chemical genetics. Chem. Rev. 106: 2476-2530.
111. Wang N, Zhang H, Zhang BQ, Liu W, Zhang Z, Qiao M, et al. 2014. Adenovirus-mediated efficient gene transfer into cultured three-dimensional organoids. PLoS One 9: e93608.
112. Wells JA, McClendon CL. 2007. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
113. Weston CR, Davis RJ. 2001. Signal transduction: Signaling specificity - a complex affair. Science 292: 2439-2440.
114. Wiedenheft B, Sternberg SH, Doudna JA. 2012. RNAguided genetic silencing systems in bacteria and archaea. Nature 482: 331-338.
115. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. 2008. Molecular imaging in drug development. Nat. Rev. Drug Discov. 7: 591-607.
116. Wink S, Hiemstra S, Huppelschoten S, Danen E, Niemeijer M, Hendriks G, et al. 2014. Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment. Chem. Res. Toxicol. 27: 338-355.
117. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. 2013. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154: 1370-1379.
118. Zanella F, Lorens JB, Link W. 2010. High content screening: Seeing is believing. Trends Biotechnol. 28: 237-245.
119. Zhou Y, Zhu S, Cai C, Yuan P, Li C, Huang Y, Wei W. 2014. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509: 487-491.
120. Ziauddin J, Sabatini DM. 2001. Microarrays of cells expressing defined cDNAs. Nature 411: 107-110.